# A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

> **NCT05755035** · PHASE2,PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 65 (actual)

## Conditions studied

- Primary Immunodeficiency Diseases (PID)

## Interventions

- **BIOLOGICAL:** TAK-881
- **BIOLOGICAL:** HYQVIA

## Key facts

- **NCT ID:** NCT05755035
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-24
- **Primary completion:** 2026-01-20
- **Final completion:** 2026-01-20
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2026-02-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05755035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05755035, "A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05755035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*